Lenvatinib Mesylate Intermedia CAS 205448-65-3 Puritas >98.0% (HPLC) Factory Featured Image

Lenvatinib Mesylate Intermedia CAS 205448-65-3 Munditia >98.0% (HPLC) Factory

Description:

Nomen chemicum: Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylatum

CAS: 205448-65-3

Puritas: >98.0% (HPLC)

Aspectus: Off-White ad flavescens pulveris

Medium de Lenvatinib Mesylate CAS 857890-39-2

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Ruifu Chemical Supple Lenvatinib Mesylate media cum puritate
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl) -3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylatus CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylatus CAS 205448-66-4

Chemical Properties:

Nomen chemicum	Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylatum
Synonyma	1,4-Dihydro-7-Methoxy-4-Oxo-6-Quinolinecarboxylic Acidum Methyl Ester;7-Methoxy-4-Oxo-1,4-Dihydro-Quinoline-6-Carboxylic Acidum Methyl Ester;Lenvatinib medium 3
CAS Number	205448-65-3
CATTUS Number	RF-PI1973
Stock Status	In Stock, Productio Capacitas 50 MT/Annus
Formulae hypotheticae	C12H11NO4
M. Pondus	233.22
Ferveret	421.0±45.0℃
Density	1.267±0.060 g/cm3
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Off-White ad Yellowish pulveris
Puritas / Analysis Methodus	>98.0% (HPLC)
Damnum in Siccatio	<1.00%
Residere in Ignition	<0.50%
Totalis immunditias	<2.00%
H-NMR	Conformat ut Structure
Test Standard	Enterprise Standard
Consuetudinem	Pharmaceutical intermedia

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

FAQ:

Applicatio:

Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylatus (CAS: 205448-65-3) medius est Mesylate Lenvatinib (CAS: 857890-39-2).Lenvatinib, sub nomine Lenvima apud alios venditum, est anti-cancri medicamen ad curationem quarundam generis cancri thyroideae et etiam carcinomata alia.Ab Eisai Co evoluta est et ut multiplex inhibitor inhibitor contra VEGFR1, VEGFR2 et VEGFR3 kinases agit.Lenvatinib approbatur (ab 2015) pro curatione cancri thyroideae differentiatae, quae vel localiter recurrens vel metastatica, progressiva est, nec curationi iodi radioactivo (radioiodine) respondet.Mense Maio 2016, US Cibus et Administration medicamentis (FDA) id approbavit (in compositione cum everolimo) ad curationem carcinomatis renalis provectae sequentem unum prioratum therapiae anti-angiogenicae.Medicamentum etiam in US et in Unione Europaea approbatur pro carcinomate hepatocellulare, quod surgice removeri non potest in aegris, qui cancer theraphim per os vel iniectionem non receperunt.